MENLO PARK, Calif.--(BUSINESS WIRE)--Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced the hiring of medical device industry veteran Reynaldo Quintana as Vice President of Engineering.
“We are pleased to have Reynaldo join the Kedalion team as we progress toward our next developmental milestones. With nearly 20 years of experience in biomedical engineering and a proven track record in medical device development, Reynaldo will play a key role in refining and industrializing our AcuStream platform,” said Peter Noymer, PhD, President and Chief Executive Officer, Kedalion Therapeutics.
Mr. Quintana joins Kedalion from Fontem Ventures B.V., where he was Senior Director of Global Engineering leading product development for next-generation platforms. Previously, he led mechanical device development at Alexza Pharmaceuticals which obtained US and EU approval for Adasuve®, the first inhalable treatment for acute agitation. Mr. Quintana has also held management positions with leading companies such as NJOY, Inc., ZOLL Medical Corporation (formerly Revivant), Aerogen, and IDEO, and has served as an engineering and product development consultant to Sunovion Pharmaceuticals, Genentech and Elevation Pharmaceuticals. He is an inventor or co-inventor on 18 patents related to medical devices and drug delivery systems. Mr. Quintana received a B.S. in mechanical engineering from the University of Maryland College Park and a B.S. in physics from Frostburg State University, and an M.S. in biomedical engineering from The Catholic University of America.
About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com.